Lee Landenberger

Atlanta

Staff Writer at BioWorld

Co-Host at The BioWorld Insider Podcast

Journalist at Clarivate

Featured in: Favicon

bioworld.com Favicon

reliasmedia.com Favicon

clarivate.com

Articles

ASCO 2025: It’s time for more trust in AI, panel says

1 week ago | bioworld.com | Lee Landenberger

Home » ASCO 2025: It’s time for more trust in AI, panel saysASCO 2025: It’s time for more trust in AI, panel saysDespite the advancement of AI and machine learning technologies and their incorporation into cancer treatment and drug development, a lack of trust and understanding of these new approaches is impeding care and treatment. BioWorld Clinical Conferences American Society of Clinical Oncology Cancer Oncology
Daiichi and Merck pull accelerated approval BLA for ADC

1 week ago | bioworld.com | Lee Landenberger

Daiichi and Merck pull accelerated approval BLA for ADCDaiichi Sankyo Co. Ltd. and Merck & Co. Inc. have voluntarily pulled the BLA for accelerated approval tied to their HER3-directed antibody-drug conjugate (ADC) in treating EGFR-mutated non-small-cell lung cancer. The partnership in the expanding ADC space began nearly two years ago in a $22 billion deal. BioWorld Clinical Regulatory Cancer Antibody-drug conjugate U.S. FDA
Spero with white knight GSK succeed with UTI treatment

1 week ago | bioworld.com | Lee Landenberger

Spero with white knight GSK succeed with UTI treatmentGSK plc knew a good thing when it swooped in nearly three years ago to rescue Spero Therapeutics Inc.’s oral antibiotic from a complete response letter (CRL). New pivotal phase III study data showed tebipenem pivoxil hydrobromide (HBr) for complicated urinary tract infections (cUTI), including pyelonephritis, hit its primary endpoint. BioWorld Clinical Infection Small molecule
City hits the town with $1B-plus deal with Biogen

1 week ago | bioworld.com | Lee Landenberger

City hits the town with $1B-plus deal with BiogenA development deal with Biogen Inc. could eventually bring City Therapeutics Inc. about $1 billion in milestone payments. It’s a step in the direction the company had been going: looking for the right partners, including those from big pharma. Privately held City Therapeutics is getting $46 million in the deal. That includes $16 million as an up-front payment and an investment of $30 million in exchange for a City Therapeutics convertible note.
Cinclus and Zentiva have a plan for reflux in Europe

2 weeks ago | bioworld.com | Lee Landenberger

Cinclus and Zentiva have a plan for reflux in EuropeCinclus Pharma Holding AB has chosen Zentiva k.s. to handle manufacturing and commercialization duties in Europe for linaprazan glurate, which is being developed to treat severe erosive gastroesophageal reflux disease. Zentiva is receiving SEK2.4 billion (US$249 million) in the deal, which includes SEK2.4 billion (US$14.72 million) up front, plus regulatory and commercial milestones. BioWorld Deals and M&A Gastrointestinal Small molecule
Like glue: Orionis and Genentech begin their second collaboration

2 weeks ago | bioworld.com | Lee Landenberger

Like glue: Orionis and Genentech begin their second collaborationOrionis Biosciences Inc. is sticking with Genentech Inc. in a second deal to discover small-molecule monovalent glue therapies for treating cancer. Privately held Orionis is getting $105 million up front and could earn more than $2 billion in R&D, development, commercial and net sales milestones, plus royalties. BioWorld Deals and M&A Collaboration Cancer Neurology/psychiatric Small molecule
Beckley’s psychedelic reduces depression

2 weeks ago | bioworld.com | Lee Landenberger

Beckley’s psychedelic reduces depression The credibility gap in psychedelic drug development continues to narrow with positive top-line data from a Beckley Psytech Ltd. phase IIa study in depression. The results keep the treatment into a tight race with GH Research plc, which also has an inhalable drug in development. BioWorld Clinical Neurology/psychiatric Small molecule U.S.
Protagenic and Phytanix merger prompts a stock surge

2 weeks ago | bioworld.com | Lee Landenberger

Protagenic and Phytanix merger prompts a stock surgeThe merger of Protagenic Therapeutics Inc. and Phytanix Bio Inc. combines two different approaches to treating obesity and metabolic issues.
Incyte adds more FDA approvals for Zynyz in cancer

3 weeks ago | bioworld.com | Lee Landenberger

Incyte adds more FDA approvals for Zynyz in cancerIncyte Corp.’s Zynyz (retifanlimab-dlwr) has received another U.S. FDA approval and put some distance between it and a 2021 complete response letter. The FDA gave the humanized monoclonal antibody targeting PD-1 the nod for first-line treatment of adults with inoperable locally recurrent or metastatic squamous cell carcinoma of the anal canal. That makes it the only approved first-line treatment for this cancer.
Septerna joins a $2.2B obesity deal with Novo

3 weeks ago | bioworld.com | Lee Landenberger

Septerna joins a $2.2B obesity deal with NovoIn a deal that could top out at about $2.2 billion, Septerna Inc. is getting $200 million up front from Novo Nordisk A/S in a collaboration to develop oral treatments for obesity, type 2 diabetes and other cardiometabolic indications.